AstraZeneca debuts new patient assistance effort

Share this article:
“Healthcare for people” is the slogan used in a new ad from AstraZeneca, part of a national push to draw attention to the firm's patient-assistance efforts.

The ad made its debut in publications such as The Wall Street Journal, USA Today, Newsweek, Jet and Inland Empire Hispanic News. Web placement includes WSJ.com.

“This is a long-term commitment of AstraZeneca to communicate news about our patient assistance program…as a reflection of what our company stands for,” Abby Baron, AZ manager, media relations, said by e-mail.

The firm expanded its main assistance program to help qualifying families of four earning $60,000 or less per year (up from $50,000) or qualifying individuals earning $30,000 or less per year (up from $24,500), a change it says could help an additional 3.8 million people. It also recently announced a new program that provides savings on AZ drugs to Medicare Part D beneficiaries, as well as 2007 community-based education and outreach initiatives in support of Part D.

Both online and print ads promote AZandMe.com and use the tagline “Healthcare for people. Imagine that.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...